Latest news with #GEM®
Yahoo
10-04-2025
- Business
- Yahoo
Establishment Labs Provides Preliminary First Quarter Results and Announces an Investor Day on June 12
NEW YORK, April 10, 2025--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, provided preliminary first quarter 2025 sales results and announced that it will host an analyst and investor event in New York City on June 12, 2025. Establishment Labs' preliminary unaudited revenue for the first quarter of 2025 is expected to be approximately $41.4 million, including approximately $6.2 million from Motiva sales in the United States. On June 12, Establishment Labs' leadership team and invited plastic surgeons will present an update on the recent launch of Motiva in the United States, the company's innovation roadmap, and the financial outlook. A live and archived webcast of presentations and Q&A sessions on June 12 will be available on the "Investors" section of the Establishment Labs website at In-person attendance at the event is limited and requires advanced registration. Please email: ir@ for further information. "The second quarter appears strong, and the United States launch continues to accelerate," said Peter Caldini, Establishment Labs' Interim CEO. "Average orders in March surpassed 100 per day, and we expect this growth to continue, making our launch one of the fastest in aesthetic history. We have not seen any disruption to our business from recent events and affirm our previous commentary and guidance on revenue of $205 to $210 million for 2025. As currently contemplated, tariffs would represent less than a 50-basis point gross margin impact and do not change our trajectory of turning EBITDA positive in 2025 and cash flow positive in 2026. At our investor day, we look forward to providing an update on our United States launch as well as detailing our pipeline, timeline, and launch strategy for the additional products coming to market in the United States." About Establishment Labs Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women's health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countries. With over four million Motiva® devices delivered to plastic and reconstructive surgeons since 2010, the Company's products have created a new standard for safety and patient satisfaction. The company's minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation and mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company's first biosensor Zen°™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2024 and FDA 21 CFR 820. Please visit our website for additional information at Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). You can find many (but not all) of these statements by looking for words such as "approximates," "believes," "expects," "anticipates," "estimates," "intends," "plans," "intends to," "would," "will," "may" or other similar expressions in this press release. Any statements that refer to projections of our future financial or operating performance, anticipated trends in our business, our goals, strategies, focus and plans, including related product development and commercialization and regulatory approvals, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, related to the company's performance are forward-looking statements. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995. We caution investors that any forward-looking statements presented in this report, or that we may make orally or in writing from time to time, are expressions of our beliefs and expectations based on currently available information at the time such statements are made. Such statements are based on assumptions, and the actual outcome will be affected by known and unknown risks, trends, uncertainties, and factors that are beyond our control. Although we believe that our assumptions are reasonable, we cannot guarantee future performance, and some will inevitably prove to be incorrect. As a result, our actual future results and the timing of events may differ from our expectations, and those differences may be material. Factors, among others, that could cause actual results and events to differ materially from those described in any forward-looking statements include risks and uncertainties relating to: our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product offerings; the rate of adoption of our products by healthcare providers or other customers; the success of our marketing initiatives; the safe and effective use of our products; our ability to protect our intellectual property; our future expansion plans and capital allocation; our ability to expand upon and/or secure sources of credit or capital; our ability to develop and maintain relationships with qualified suppliers to avoid a significant interruption in our supply chains; our ability to attract and retain key personnel; our ability to scale our operations to meet market demands; the effect on our business of existing and new regulatory requirements; and other economic and competitive factors. These and other factors that could cause or contribute to actual results differing materially from our expectations include, among others, those risks and uncertainties discussed in the company's annual report on Form 10-K filed on February 28, 2025, which risks and uncertainties may be updated in the future in other filings made by the company with the Securities and Exchange Commission. The risks included in those documents are not exhaustive, and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for us to predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We are not undertaking any obligation to update any forward-looking statements. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on known results and trends at the time they are made, to anticipate future results or trends. View source version on Contacts Investor/Media Contact: Raj Denhoy415 828-1044rdenhoy@ Sign in to access your portfolio
Yahoo
25-02-2025
- Business
- Yahoo
2025 SUPER BOWL ADS FUMBLE AGAIN: How Ignoring Women Cost Brands ROI For the 12th Year
ABX Advertising Benchmark Index™ and ANA SeeHer™, partners and co-developers of GEM®, (the Gender Equality Measure), today announced that Super Bowl 2025 ads were, once again, less effective than regular brand ads airing in the prior 12-month period. Amazingly, this trend has held true for 12 years (except for 2020 during Covid). Could the fact that these ads had little appeal to women be a reason for these declining scores? Super Bowl Ads vs Same Brand Ads Prior 12 Months Super Bowl Average ABX Index Scores by KPI GEM vs ABX Reputation Index New York, Feb. 25, 2025 (GLOBE NEWSWIRE) -- – ABX Advertising Benchmark Index™ and ANA SeeHer™, partners and co-developers of GEM®, (the Gender Equality Measure), today announced that Super Bowl 2025 ads were, once again, less effective than regular brand ads airing in the prior 12-month period. Amazingly, this trend has held true for 12 years (except for 2020 during Covid). Could the fact that these ads had little appeal to women be a reason for these declining scores? (See chart below) ABX Advertising Benchmark Index™ is a leading advertising effectiveness company that has measured half-a-million ads, across all media types, globally to date. SeeHer, launched by the Association of National Advertisers (ANA) in 2016, is the leading global movement to eliminate gender bias in advertising, marketing, media, and entertainment. GEM® scores are highly correlated to improving brand health and increasing sales. It is considered the 'gold standard' for measuring gender bias worldwide. This chart shows that regular ads have outperformed Super Bowl ads for the same brandsover the last 12 months, for the past 12 years. Only 11% of Super Bowl 2025 ads were above the ABX Index™ TV norm of 108.5, 37% were at norm, and 52% were below norm. Why are so many Super Bowl ads, at $8 million a pop, missing the mark? The ABX KPI scores below provide some insights on where these ads go wrong. While Super Bowl ads are more Likeable and Re-watchable than regular brand ads, they fall short in Brand Reputation, Purchase Intent, and other Calls-to-Action. If ads don't stimulate Action or increase Reputation, are they worth $8 million to air? Here are the differences between Super Bowl and regular ads for the same brands for the prior 12-month period: Super Bowl ads usually score high in Likeability and Watchability, but not so much inBrand Reputation, Purchase Intent and Calls-to-Action that drive Brand: Clear which brand is being advertisedBrand Reputation: Feel better, worse, no different about the brand after being exposed to the adPurchase Intent: As a result of seeing this ad, intend to purchaseCalls to Action: As a result of seeing this ad, any of six actions are takenLikeability: Like this ad based on a 10-point scaleSee Again: I would be willing to see this ad againSuper Bowl ads Aren't Resonating with Women Watching the Game Women have always been football fans. However, advertising has not acknowledged female fans, nor appealed to them, which is likely a contributing factor of low Super Bowl ad scores. Women's economic impact this year extended beyond viewership. ABX data showed that 40% of each female viewer spent an average of $30 or more on Super Bowl-related purchases such as food, party supplies, and merchandise. Beyond game day, women wield $31.5 trillion in purchasing power and influence 85% of consumer decisions. While viewership from female fans should emphasize the growing importance of this demographic, women (female characters) are often absent, overshadowed, or inauthentically portrayed in ads. Female Representation in Ads Fall Short For this part of the analysis, we leveraged nine years of Super Bowl creative testing results and trends from the ABX Index and GEM® metric. In 2025, women were present in 81% of Super Bowl ads, a drop of 10 points from 2024. Only one ad had a solo female character. Thirteen percent featured only male characters, all of which were at or below the ABX TV norm. Eighty percent of ads featured both male and female characters. While women were present in Super Bowl ads, they didn't see themselves represented accurately. The Gender Equality Measure (GEM®) for female characters was rated lower by female respondents than by male respondents. Missing the Mark with Female Fans is a Missed Opportunity Not targeting female fans correlates with weaker purchase intent among women. For Super Bowl ads, the ABX Purchase Intent Index was only 87 for women compared to 124 for men. Improving the portrayal of women is highly correlated with improved Reputation and Call-to-Action Scores (includes website visits, search, purchases, recommendations). As explained below, as the GEM score increases, so do Reputation and CTAs. The chart above shows that for every GEM® point score improvement, Brand Reputation improves by 1.7 points, for a 70% increase. The same is true with Calls-To-Action. As GEM® increases, CTAs improve by 0.5 points, or 25%. The measure of overall effectiveness, the ABX Index, improves 0.4, or 20%, for every GEM® point of improvement for brands whose ads accurately portrayed women vs. those that did not. Conclusion Super Bowl advertisers continue to miss the mark on creative, which significantly reduces the impact of their substantial investment. And despite the increasing interest and viewership by women, Super Bowl ads fail to resonate with them. For Super Bowl and non-Super Bowl ads, brands can benefit by prioritizing inclusivity and authenticity, leveraging best practices to optimize their investment and connect with one of the most influential consumer segments in the market …. WOMEN! Contributors Gary Getto, President & Co-Founder, ABX Advertising Benchmark IndexGary@ Yatisha Forde, Sr. Director, Insights & Thought Leadership, SeeHeryforde@ Press Inquiries:Angela Jeffrey, VP Brand Management, ABXangie@ Contact us HereAbout GEM® GEM®, spearheaded by SeeHer and ABX Advertising Benchmark Index, is a globally renowned ESOMAR (European Society for Opinion and Marketing Research) award-winning effectiveness measurement methodology. GEM® evaluates gender portrayals in advertising and content and is highly correlated to improving brand health, as well as increasing sales. Advertisements delivering high GEM® scores have yielded double-digit increases in brand reputation, brand choice, purchase intent, calls to action, and brand loyalty. Moreover, ads with elevated GEM® scores have been correlated with driving significant sales lifts across genders, races/ethnicities, and generations, up to 10X higher than ads with low GEM® scores. About Advertising Benchmark Index ABX Advertising Benchmark Index ( is an ANA SeeHer partner and co-developer of GEM®. It is a techno-research company focused on driving ROAS & ROI through its Global Integrated Single Solution. Marketers, through the ABX Global Multimedia Platform, can evaluate the effectiveness of all their creative across all media types and channels, and against their competitors, in 75+ countries. ABX has evaluated half-a-million live, in-market ads through its syndicated system, and offers a wide variety of standard and customized solutions. About SeeHer SeeHer is the leading global movement to eliminate gender bias in marketing, media, and entertainment. Launched in 2016 by the Association of National Advertisers (ANA), SeeHer's coalition of leaders is committed to setting the gender equality agenda for the industry and driving growth for their businesses. To help its members benchmark success and become catalysts for change, SeeHer spearheaded the development of the Gender Equality Measure (GEM®), the first research methodology that quantifies gender bias in ads and programming. A winner of the prestigious ESOMAR Research Effectiveness Award, GEM® is the global measurement standard, proving that content accurately portraying women and girls dramatically increases purchase intent and brand reputation. SeeHer's suite of training and resources, including GEM®, enables marketers to prioritize best practices as part of an always-on approach to driving growth. The movement includes the following vertical expertise: SeeHer in Sports, SeeHer Entertainment, SeeHer Health, and the SeeHer Media Task Force. Visit to join the movement and follow SeeHer on LinkedIn and Instagram. Sources: ABX Advertising Benchmark Index, SeeHer, (Gender Equality Measure) 2017-2025 Super Bowl Ad Analysis Attachments Super Bowl Ads vs Same Brand Ads Prior 12 Months Super Bowl Average ABX Index Scores by KPI GEM vs ABX Reputation Index CONTACT: Angela Jeffrey, VP Brand Management, ABX angie@ in to access your portfolio
Yahoo
14-02-2025
- Business
- Yahoo
Establishment Labs to Announce Fourth Quarter 2024 Financial Results on February 26
NEW YORK, February 14, 2025--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2024, after the market closes on Wednesday, February 26, 2025, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or (201) 689-8037 (International) and use conference ID number 13750828. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at About Establishment Labs Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women's health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countries. With over four million Motiva® devices delivered to plastic and reconstructive surgeons since 2010, the Company's products have created a new standard for safety and patient satisfaction. The company's minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation and mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company's first biosensor Zen°™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patents applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2024 and FDA 21 CFR 820. Please visit our website for additional information at View source version on Contacts Investor/Media Contact: Raj Denhoy415 828-1044rdenhoy@ Sign in to access your portfolio
